Cesca Therapeutics Inc. , an autologous cell-based regenerative medicine company, today announced a corporate update on Cesca's clinical trial program in CLI and AMI. As previously announced in early January, the Company received a letter from the U.S. Food and Drug Administration responding to the Company's submittal of its Investigational Device Exemption application for a pivotal phase three clinical trial for the treatment of no-option patients with CLI.
http://www.biospace.com/news_story.aspx?StoryID=371903&full=1
http://www.biospace.com/news_story.aspx?StoryID=371903&full=1
No comments:
Post a Comment